Here is Why Zoetis (ZTS) is One of the Best NYSE Stocks According Analysts

Zoetis Inc. (NYSE:ZTS) is one of the best NYSE stocks to buy according to Wall Street analysts. On May 7, Zoetis reported Q1 2026 revenue of $2.3 billion, a 3% increase on a reported basis but flat organically. Net income reached $601 million, with adjusted diluted EPS growing 9% to $1.53. CEO Kristin Peck noted a challenging operating environment characterized by increased price sensitivity among pet owners and intensified competition in dermatology and parasiticides, leading to a softer demand for premium products.

Performance varied significantly by region, with the US segment seeing an 8% revenue decline to $1.1 billion due to lower companion animal product sales and generic competition. In contrast, the International segment grew 17% to $1.1 billion, driven by strong demand in livestock and parasiticides, as well as a $100 million benefit from fiscal year reporting alignments. Livestock sales remained a bright spot globally, with a 7% organic increase in the US and a 14% increase internationally.

Zoetis Inc. (NYSE:ZTS) revised its full-year 2026 revenue guidance to between $9.68 and $9.96 billion, representing organic growth of 2% to 5%. The company remains focused on its pipeline of over 12 potential blockbusters and its pending acquisition of Neogen’s animal genomics business, expected to close in H2 2026.

Zoetis Inc. (NYSE:ZTS) is a global animal health company that discovers, develops, manufactures, and commercializes vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.